본문 바로가기

Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
ANNALS OF ONCOLOGY32(4) · pp.552 · 2021
피인용
Web of Science 24Scopus 27
FWCI (Scopus)
1.12
JCR IF
JCR 2020 32.976
ISSN
0923-7534

저자

  1. Yhim, H. Y.제1저자Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju
  2. Kim, T.Department of Medical Sciences, Chonnam National University Medical School, Jeollanam-do
  3. Kim, S. J.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
  4. 신호진Department of Internal Medicine, Pusan National University Hospital, Busan
  5. Koh, Y.Department of Internal Medicine, Seoul National University Hospital, Seoul
  6. Kim, J. S.Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul
  7. Park, J.Department of Internal Medicine, Gachon University Gil Medical Center, Incheon
  8. Park, G. S.Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul
  9. Kim, W. S.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
  10. Moon, J. H.교신저자Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu
  11. Yang, D. H.교신저자Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of Korea

초록

Background: Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). Patients and methods: This phase I/II study (NCT03052933) investigated the safety and efficacy of copanlisib, a phosphatidylinositol 3-kinase-alpha/-delta inhibitor, in combination with gemcitabine in 28 patients with relapsed/refractory PTCL. Patients received escalating doses of intravenous copanlisib on days 1, 8, and 15, administered concomitantly with fixed-dose gemcitabine (1000 mg/m(2) on days 1 and 8) in 28-day cycles. Results: Dose-limiting toxicity was not observed in the dose-escalation phase and 60 mg copanlisib was selected for phase II evaluation. Twenty-five patients were enrolled in phase II of the study. Frequent grade >= 3 adverse events (AEs) included transient hyperglycemia (57%), neutropenia (45%), thrombocytopenia, (37%), and transient hypertension (19%). However, AEs were manageable, and none were fatal. The overall response rate was 72% with a CR rate of 32%. Median duration of response was 8.2 months, progression-free survival was 6.9 months, and median overall survival was not reached. Combination treatment produced a greater CR rate in patients with angioimmunoblastic T-cell lymphoma than those with PTCL-not otherwise specified (55.6% versus 15.4%, respectively, P = 0.074) and progression-free survival was significantly longer (13.0 versus 5.1 months, respectively, P = 0.024). In an exploratory gene mutation analysis of 24 tumor samples, TSC2 mutation was present in 25% of patients and occurred exclusively in responders. Conclusion: The combination of copanlisib and gemcitabine is a safe and effective treatment option in relapsed/ refractory PTCLs and represents an important new option for therapy in this rare group of patients.

키워드

copanlisibgemcitabineperipheral T-cell lymphomarelapsed or refractoryphase I/II trial

식별자

Scopus EID
2-s2.0-85100172001
WoS UID
000629502100016